Curis prices USD 8.5 million offering: Curis stock gains 3.37 percent

Published on 10/20/2026 at 20:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Curis offers 16,666,680 shares on October 16, 2026. Curis stock costs EUR 0.35 on October 20, 2026, up 3.37 percent versus the Tradegate close.

Financing and price

Curis priced a USD 8.5 million offering on October 16, 2026.
The financing covers 16,666,680 shares and warrants at USD 0.51 per share.
Curis stock costs EUR 0.35 at Lang & Schwarz on October 20, 2026 at 8:09 p.m. CEST, 3.37 percent above the Tradegate close of October 19, 2026.

CRIS, US2312694084, Illustration mit AI erstellt.

Curis (US2312694084) priced a USD 8.5 million private placement on October 16, 2026, while its stock gained 3.37 percent at Lang & Schwarz. MarketScreener reported that the biotechnology company agreed to sell 16,666,680 shares, or pre-funded warrants, together with warrants for the same number of shares at USD 0.51 per share. Curis stock was trading at EUR 0.35 at Lang & Schwarz on October 20, 2026 at 8:09 p.m. CEST, up 3.37 percent versus the Tradegate close of October 19, 2026 at EUR 0.34.

Funding reaches December data

The financing is designed to extend Curis operations through initial chronic lymphocytic leukemia data from 5 to 10 patients in December 2026. The common warrants carry a USD 0.60 exercise price and become exercisable six months after issuance, while pre-funded warrants carry a USD 0.01 exercise price. StockTitan reported that Curis held USD 5.1 million in cash and equivalents on June 30, 2026.

Stock stays near its yearly low

Curis stock had a USD 0.33 to USD 33.60 52-week range on October 20, 2026, placing the Lang & Schwarz price 6.06 percent above the low and 98.96 percent below the high. The Nasdaq quote showed 92,278 shares traded and a USD 0.8 million market capitalization on October 20, 2026. The price position keeps financing terms central to the trading picture.

Valuation and reporting dates

Curis carried a negative price-to-earnings ratio of 0.03 on October 20, 2026, while no dividend yield was reported. The company develops emavusertib, an oral IRAK4 and FLT3 inhibitor, for cancer indications and is listed on the Nasdaq Capital Market under ticker CRIS.

Comparison with peers

Curis: up 3.37 percent, P/E -0.03, market capitalization USD 0.8 million.

Kura Oncology (Nasdaq, USD): up 6.75 percent, P/E -2.96, market capitalization USD 888.9 million. Ardelyx (Nasdaq, USD): up 3.69 percent, P/E -14.22, market capitalization USD 798.4 million.

What the financing changes

The offering adds capital for research and development but also introduces new shares and warrants. The financing covers 16,666,680 common shares and warrants for up to 16,666,680 shares, so future dilution remains part of the calculation for investors.

Price and financing terms

Curis stock was trading at EUR 0.35 at Lang & Schwarz on October 20, 2026 at 8:09 p.m. CEST, 3.37 percent above the Tradegate close of October 19, 2026 at EUR 0.34. The Nasdaq-listed company remains 6.06 percent above its USD 0.33 52-week low. The further course of trading is shown by the continuously updated real-time quote of Curis stock.